Key statistics
On Thursday, Aprea Therapeutics Inc (APRE:NAQ) closed at 2.92, 35.94% above the 52 week low of 2.15 set on Oct 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.92 |
---|---|
High | 3.00 |
Low | 2.90 |
Bid | 2.75 |
Offer | 3.44 |
Previous close | 3.01 |
Average volume | 14.74k |
---|---|
Shares outstanding | 5.43m |
Free float | 4.41m |
P/E (TTM) | -- |
Market cap | 15.89m USD |
EPS (TTM) | -2.81 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 15:47 GMT.
More ▼
- Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
- Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit
- Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics
- Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development
- Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
- UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
- Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
- Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
More ▼